Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.

Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02142-18. doi: 10.1128/AAC.02142-18. Print 2019 Apr.

2.

RVCL-S and CADASIL display distinct impaired vascular function.

de Boer I, Stam AH, Buntinx L, Zielman R, van der Steen I, van den Maagdenberg AMJM, de Koning EJP, Ferrari MD, de Hoon JN, Terwindt GM.

Neurology. 2018 Sep 4;91(10):e956-e963. doi: 10.1212/WNL.0000000000006119. Epub 2018 Aug 3.

PMID:
30076273
3.

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.

Krishna R, Addy C, Tatosian D, Glasgow XS, Gendrano Iii IN, Robberechts M, Haazen W, de Hoon JN, Depré M, Martucci A, Peng JZ, Johnson-Levonas AO, Wagner JA, Stoch SA.

J Clin Pharmacol. 2016 Dec;56(12):1528-1537. doi: 10.1002/jcph.773. Epub 2016 Jun 17.

4.

SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants.

Matic M, de Wildt SN, Elens L, de Hoon JN, Annaert P, Tibboel D, van Schaik RH, Allegaert K.

Ther Drug Monit. 2016 Aug;38(4):487-92. doi: 10.1097/FTD.0000000000000307.

PMID:
27082504
5.

Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.

Li CC, Vermeersch S, Denney WS, Kennedy WP, Palcza J, Gipson A, Han TH, Blanchard R, De Lepeleire I, Depré M, Murphy MG, Van Dyck K, de Hoon JN.

Br J Clin Pharmacol. 2015 May;79(5):831-7. doi: 10.1111/bcp.12547.

6.

Covariates of intravenous paracetamol pharmacokinetics in adults.

Allegaert K, Olkkola KT, Owens KH, Van de Velde M, de Maat MM, Anderson BJ; PACIA study group.

BMC Anesthesiol. 2014 Sep 13;14:77. doi: 10.1186/1471-2253-14-77. eCollection 2014.

7.

Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study.

Allegaert K, Holford N, Anderson BJ, Holford S, Stuber F, Rochette A, Trocóniz IF, Beier H, de Hoon JN, Pedersen RS, Stamer U.

Clin Pharmacokinet. 2015 Feb;54(2):167-78. doi: 10.1007/s40262-014-0191-9.

PMID:
25258277
8.

Estradiol and weight are covariates of paracetamol clearance in young women.

Beleyn B, Vermeersch S, Kulo A, Smits A, Verbesselt R, de Hoon JN, Van Calsteren K, Allegaert K.

Gynecol Obstet Invest. 2014;77(4):211-6. doi: 10.1159/000358394. Epub 2014 Mar 25.

PMID:
24686129
9.

Weight, pregnancy and oral contraceptives affect intravenous paracetamol clearance in young women.

Kulo A, Van Calsteren K, van de Velde M, Mulabegovic N, Verbesselt R, de Hoon JN, Verhaeghe J, Allegaert K.

Eur Rev Med Pharmacol Sci. 2014;18(5):599-604.

10.

Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.

Depré M, Macleod C, Palcza J, Behm M, de Lepeleire I, Han T, Panebianco D, Smith W, Blanchard R, Chodakewitz J, Murphy M, de Hoon J.

Cephalalgia. 2013 Dec;33(16):1292-301. doi: 10.1177/0333102413494272. Epub 2013 Jun 24.

PMID:
23798725
11.

The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates.

Kulo A, de Hoon JN, Allegaert K.

Int J Pharm. 2012 Oct 5;435(2):112-4. doi: 10.1016/j.ijpharm.2012.05.014. Epub 2012 May 26.

PMID:
22641171
12.

Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations.

Smits A, Kulo A, de Hoon JN, Allegaert K.

Curr Pharm Des. 2012;18(21):3119-46. Review.

PMID:
22564304
13.

Pharmacokinetics of Drugs in Neonates: Pattern Recognition Beyond Compound Specific Observations.

Smits A, Kulo A, de Hoon JN, Allegaert K.

Curr Pharm Des. 2012 Feb 27. [Epub ahead of print]

PMID:
22385063
14.

Interictal type 1 cannabinoid receptor binding is increased in female migraine patients.

Van der Schueren BJ, Van Laere K, Gérard N, Bormans G, De Hoon JN.

Headache. 2012 Mar;52(3):433-40. doi: 10.1111/j.1526-4610.2011.02030.x. Epub 2011 Nov 11.

PMID:
22077199
15.

The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.

Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E.

Platelets. 2011;22(7):495-503. doi: 10.3109/09537104.2011.565433. Epub 2011 Apr 28.

PMID:
21526889
16.

The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.

Van der Schueren BJ, Blanchard R, Murphy MG, Palcza J, De Lepeleire I, Van Hecken A, Depré M, de Hoon JN.

Br J Clin Pharmacol. 2011 May;71(5):708-17. doi: 10.1111/j.1365-2125.2010.03869.x.

17.

Does intravenous paracetamol administration affect body temperature in neonates?

Hopchet L, Kulo A, Rayyan M, Verbesselt R, Vanhole C, de Hoon JN, Allegaert K.

Arch Dis Child. 2011 Mar;96(3):301-4. doi: 10.1136/adc.2010.203778. Epub 2011 Jan 12.

PMID:
21233080
18.

Endothelial function in migraine: a cross-sectional study.

Vanmolkot FH, de Hoon JN.

BMC Neurol. 2010 Dec 1;10:119. doi: 10.1186/1471-2377-10-119.

19.

No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers.

Van der Schueren BJ, Verbrugge FH, Verbesselt R, Van Hecken A, Depré M, de Hoon JN.

Cephalalgia. 2010 Nov;30(11):1354-65. doi: 10.1177/0333102410365105. Epub 2010 Apr 7.

PMID:
20959430
20.

Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist.

Atack JR, Hallett DJ, Tye S, Wafford KA, Ryan C, Sanabria-Bohórquez SM, Eng WS, Gibson RE, Burns HD, Dawson GR, Carling RW, Street LJ, Pike A, De Lepeleire I, Van Laere K, Bormans G, de Hoon JN, Van Hecken A, McKernan RM, Murphy MG, Hargreaves RJ.

J Psychopharmacol. 2011 Mar;25(3):329-44. doi: 10.1177/0269881109354928. Epub 2010 Feb 15.

PMID:
20156926
21.

MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans.

Atack JR, Wafford KA, Street LJ, Dawson GR, Tye S, Van Laere K, Bormans G, Sanabria-Bohórquez SM, De Lepeleire I, de Hoon JN, Van Hecken A, Burns HD, McKernan RM, Murphy MG, Hargreaves RJ.

J Psychopharmacol. 2011 Mar;25(3):314-28. doi: 10.1177/0269881109354927. Epub 2010 Feb 10.

PMID:
20147571
22.

Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

Sinclair SR, Kane SA, Van der Schueren BJ, Xiao A, Willson KJ, Boyle J, de Lepeleire I, Xu Y, Hickey L, Denney WS, Li CC, Palcza J, Vanmolkot FH, Depré M, Van Hecken A, Murphy MG, Ho TW, de Hoon JN.

Br J Clin Pharmacol. 2010 Jan;69(1):15-22. doi: 10.1111/j.1365-2125.2009.03543.x.

23.

Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?

Van der Schueren BJ, Lunnon MW, Laurijssens BE, Guillard F, Palmer J, Van Hecken A, Depré M, Vanmolkot FH, de Hoon JN.

J Clin Pharmacol. 2009 Mar;49(3):281-90. doi: 10.1177/0091270008329548.

PMID:
19246728
24.

Covariates of tramadol disposition in the first months of life.

Allegaert K, van den Anker JN, de Hoon JN, van Schaik RH, Debeer A, Tibboel D, Naulaers G, Anderson BJ.

Br J Anaesth. 2008 Apr;100(4):525-32. doi: 10.1093/bja/aen019. Epub 2008 Feb 26.

25.

Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model.

Van der Schueren BJ, Rogiers A, Vanmolkot FH, Van Hecken A, Depré M, Kane SA, De Lepeleire I, Sinclair SR, de Hoon JN.

J Pharmacol Exp Ther. 2008 Apr;325(1):248-55. doi: 10.1124/jpet.107.133868. Epub 2008 Jan 23.

PMID:
18216286
26.

Inter-individual variability in propofol pharmacokinetics in preterm and term neonates.

Allegaert K, Peeters MY, Verbesselt R, Tibboel D, Naulaers G, de Hoon JN, Knibbe CA.

Br J Anaesth. 2007 Dec;99(6):864-70. Epub 2007 Oct 26.

27.

Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.

Lai E, Wenning LA, Crumley TM, De Lepeleire I, Liu F, de Hoon JN, Van Hecken A, Depré M, Hilliard D, Greenberg H, O'Neill G, Metters K, Gottesdiener KG, Wagner JA.

Clin Pharmacol Ther. 2008 Jun;83(6):840-7. Epub 2007 Sep 19.

PMID:
17882161
28.

Increased C-reactive protein in young adult patients with migraine.

Vanmolkot FH, de Hoon JN.

Cephalalgia. 2007 Jul;27(7):843-6.

PMID:
17668468
29.

Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging.

Van der Schueren BJ, de Hoon JN, Vanmolkot FH, Van Hecken A, Depre M, Kane SA, De Lepeleire I, Sinclair SR.

Br J Clin Pharmacol. 2007 Nov;64(5):580-90. Epub 2007 Jun 19.

30.

Altered arterial function in migraine of recent onset.

Vanmolkot FH, Van Bortel LM, de Hoon JN.

Neurology. 2007 May 8;68(19):1563-70. Epub 2007 Apr 25.

PMID:
17460157
31.

The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers.

Van Hecken A, Depré M, De Lepeleire I, Thach C, Oeyen M, Van Effen J, Laethem T, Mazina K, Crumley T, Wenning L, Gottesdiener KM, Deutsch P, Clement P, Lai E, de Hoon JN.

Eur J Clin Pharmacol. 2007 Feb;63(2):135-41. Epub 2007 Jan 3.

PMID:
17200838
32.

Acute effects of sumatriptan on aortic blood pressure, stiffness, and pressure waveform.

Vanmolkot FH, de Hoon JN.

Clin Pharmacol Ther. 2006 Jul;80(1):85-94.

PMID:
16815320
33.

Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by CGRP8-37: evaluation of a human in vivo pharmacodynamic model.

Vanmolkot FH, Van der Schueren BJ, de Hoon JN.

Clin Pharmacol Ther. 2006 Mar;79(3):263-73. Epub 2006 Feb 7.

PMID:
16513450
34.

Forearm vascular response to nitric oxide and calcitonin gene-related peptide: comparison between migraine patients and control subjects.

de Hoon JN, Smits P, Troost J, Struijker-Boudier HA, Van Bortel LM.

Cephalalgia. 2006 Jan;26(1):56-63.

PMID:
16396667
35.

Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.

Depré M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P, Petty KJ, Majumdar A, Crumley T, Panebianco D, Bergman A, de Hoon JN.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):341-6. Epub 2005 Jun 28.

PMID:
15983826
37.

Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans.

de Hoon JN, Pickkers P, Smits P, Struijker-Boudier HA, Van Bortel LM.

Clin Pharmacol Ther. 2003 Apr;73(4):312-21.

PMID:
12709721
38.

Cranial and peripheral interictal vascular changes in migraine patients.

de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, van Bortel LM.

Cephalalgia. 2003 Mar;23(2):96-104.

PMID:
12603365
39.

Effects of enteric-coated, low-dose aspirin on parameters of platelet function.

Van Hecken A, Juliano ML, Depré M, De Lepeleire I, Arnout J, Dynder A, Wildonger L, Petty KJ, Gottesdiener K, De Hoon JN.

Aliment Pharmacol Ther. 2002 Sep;16(9):1683-8.

40.

Non-invasive assessment of selective 5-HT(1B/1D)-receptor agonist-induced peripheral vascular effects in humans: comparison of different techniques.

Vanmolkot FH, de Hoon JN, Barrington P, Peck RW, Dallow NS, Williams PM, McColm J.

Eur J Clin Pharmacol. 2002 Aug;58(5):303-8. Epub 2002 Jul 5.

PMID:
12185552
41.

Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data.

de Hoon JN, Poppe KA, Thijssen HH, Struijker-Boudier HA, Van Bortel LM.

Br J Clin Pharmacol. 2001 Jul;52(1):45-51.

42.

Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches.

de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, Van Bortel LM.

Clin Pharmacol Ther. 2000 Oct;68(4):418-26.

PMID:
11061582
43.

Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide.

Vanmolkot FH, de Hoon JN, van de Ven LL, Van Bortel LM.

J Hum Hypertens. 1999 Aug;13(8):559-63.

PMID:
10455479
44.

No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics.

de Hoon JN, Thijssen HH, Beysens AJ, Van Bortel LM.

Br J Clin Pharmacol. 1997 Oct;44(4):399-401.

45.

Quality of life comparison between bisoprolol and nifedipine retard in hypertension.

de Hoon JN, Vanmolkot FH, van de Ven LL, Van Bortel LM.

Cardiovasc Drugs Ther. 1997 Jul;11(3):465-71.

PMID:
9310275
46.

Pneumocystis carinii pneumonia. Review of 32 cases in immunocompromised hosts.

de Hoon JN, Peetermans WE, Bobbaers HJ.

Acta Clin Belg. 1997;52(1):19-26.

PMID:
9085615
47.

Pharmacological properties of nebivolol in man.

Van Bortel LM, de Hoon JN, Kool MJ, Wijnen JA, Vertommen CI, Van Nueten LG.

Eur J Clin Pharmacol. 1997;51(5):379-84.

PMID:
9049578

Supplemental Content

Loading ...
Support Center